Show simple item record

dc.contributor.authorVan de Water, Sandra G.P.
dc.contributor.authorPotgieter, Christiaan A.
dc.contributor.authorVan Rijn, Piet A.
dc.contributor.authorVan Gennip, René G.P.
dc.contributor.authorWright, Isabel M.
dc.date.accessioned2016-09-21T07:09:07Z
dc.date.available2016-09-21T07:09:07Z
dc.date.issued2015
dc.identifier.citationVan de Water, S.G.P. et al. 2015. VP2 exchange and NS3/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV. Journal of virology, 89(17):8764-8772. [http://dx.doi.org/10.1128/JVI.01052-15]en_US
dc.identifier.issn0022-538X
dc.identifier.issn1098-5514 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/18851
dc.identifier.urihttp://dx.doi.org/10.1128/JVI.01052-15
dc.identifier.urihttp://jvi.asm.org/content/89/17/8764
dc.description.abstractAfrican horse sickness virus (AHSV) is a virus species in the genus Orbivirus of the family Reoviridae. There are nine serotypes of AHSV showing different levels of cross neutralization. AHSV is transmitted by species of Culicoides biting midges and causes African horse sickness (AHS) in equids, with a mortality rate of up to 95% in naive horses. AHS has become a serious threat for countries outside Africa, since endemic Culicoides species in moderate climates appear to be competent vectors for the related bluetongue virus (BTV). To control AHS, live-attenuated vaccines (LAVs) are used in Africa. We used reverse genetics to generate “synthetic” reassortants of AHSV for all nine serotypes by exchange of genome segment 2 (Seg-2). This segment encodes VP2, which is the serotype-determining protein and the dominant target for neutralizing antibodies. Single Seg-2 AHSV reassortants showed similar cytopathogenic effects in mammalian cells but displayed different growth kinetics. Reverse genetics for AHSV was also used to study Seg-10 expressing NS3/NS3a proteins. We demonstrated that NS3/NS3a proteins are not essential for AHSV replication in vitro. NS3/NS3a of AHSV is, however, involved in the cytopathogenic effect in mammalian cells and is very important for virus release from cultured insect cells in particular. Similar to the concept of the bluetongue disabled infectious single animal (BT DISA) vaccine platform, an AHS DISA vaccine platform lacking NS3/NS3a expression was developed. Using exchange of genome segment 2 encoding VP2 protein (Seg-2[VP2]), we will be able to develop AHS DISA vaccine candidates for all current AHSV serotypesen_US
dc.language.isoenen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.titleVP2 exchange and NS3/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSVen_US
dc.typeArticleen_US
dc.contributor.researchID10085637 - Potgieter, Abraham Christiaan
dc.contributor.researchID24551287 - Van Rijn, Petrus Antonius


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record